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Abstract
Background: α1-Antitrypsin deficiency (AATD) is associ-
ated with a high risk of developing lung and liver disease. 
Despite being one of the most common hereditary dis-
orders worldwide, AATD remains under-diagnosed and 
prolonged delays in diagnosis are usual. The aim of this 
study was to validate the use of buccal swab samples and 
serum circulating DNA for the complete laboratory study 
of AATD.
Methods: Sixteen buccal swab samples from previously 
characterized AATD patients were analyzed using an 
allele-specific genotyping assay and sequencing method. 
In addition, 19 patients were characterized by quantifi-
cation, phenotyping and genotyping using only serum 
samples.
Results: The 16 buccal swab samples were correctly char-
acterized by genotyping. Definitive results were obtained 
in the 19 serum samples analyzed by quantification, phe-
notyping and genotyping, thereby performing the com-
plete AATD diagnostic algorithm.
Conclusions: Buccal swab samples may be useful to 
expand AATD screening programs and family studies. 
Genotyping using DNA from serum samples permits the 
application of the complete diagnostic algorithm without 
delay. These two methods will be useful for obtaining more 
in depth knowledge of the real prevalence of patients with 
AATD.
Keywords: α1-antitrypsin deficiency; α1-antitrypsin geno-
typing; buccal swab sample; serum sample.
Introduction
α1-Antitrypsin deficiency (AATD) is one of the most 
common hereditary disorders worldwide and is a well rec-
ognized genetic risk factor for pulmonary and liver disease 
[1, 2]. In rare cases, skin diseases such as panniculitis and 
vasculitis may occur [3, 4]. α1-antitrypsin (AAT) is encoded 
by the protease inhibitor (PI) gene SERPINA1, which is 
organized into four encoding (II, III, IV and V) and three 
noncoding (Ia, Ib and Ic) exons [5]. AAT is a highly poly-
morphic protein with over 120 alleles. The normal allele 
is designated PI M and the most common deficient alleles 
are PI S (p.Glu264Val) and PI Z (p.Glu342Lys) [6]. These 
deficient variants are associated with AAT serum levels of 
40% and 10%–20% of the normal range level, respectively. 
Therefore, the PI Z allele is characterized as a severe defi-
ciency variant. PI Z homozygosity is also the phenotype 
most often associated with both lung disease, attributable 
to the low serum concentration, and liver disease, attrib-
utable to hepatocyte endoplasmic reticulum retention of 
the polymerized variant protein [7, 8]. Nevertheless, there 
are at least 30 other AAT alleles, called “rare”, which are 
associated with significantly reduced or absent plasma 
AAT levels [9].
Although AAT deficiency is the most common heredi-
tary disease diagnosed in adults, there is a generalized 
lack of knowledge in the medical community about this 
disorder [10, 11]. Many physicians are not aware that pul-
monary conditions, such as chronic obstructive pulmo-
nary disease or liver disease may actually be due to AATD 
[11]. Panniculitis is another clinical manifestation of AATD 
and may also be significantly underdiagnosed [4]. In addi-
tion, many subjects with severe AATD may have no clini-
cal symptoms [12].
The diagnostic algorithm of AATD used in our labo-
ratory and reported previously [13], is based on the 
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quantitative measurement of AAT levels followed by 
AAT phenotyping and genotyping. AAT levels are mainly 
measured by nephelometry, and phenotype analysis is 
performed by isoelectric focusing (IEF) on agarose gels. 
This technique separates the various isoforms of AAT 
based on their migration in a pH gradient of 4.2–4.9 [14]. 
Serum or plasma samples are needed for these techniques 
[15]. Molecular analysis of the AAT gene (genotyping) is 
performed using methods such as allele-specific geno-
typing or exonic sequencing of the SERPINA1 gene. The 
allele-specific genotyping assay is used for detecting the 
more prevalent PI S and PI Z deficiency alleles and the 
rare variant PI Mmalton (p.Phe52del). Direct sequencing 
of SERPINA1 encoding regions is carried out when the 
allele-specific genotyping assay is unable to provide com-
plete identification of both AAT alleles. Additional DNA 
extraction from whole blood or dried blood spot (DBS) is 
usually required for AAT genotyping, causing a significant 
delay in AATD diagnosis. Serum samples are required to 
perform the first steps of AAT diagnosis, and thus, the use 
of DNA obtained from this kind of sample would reduce 
the time to obtain definitive results. Moreover, a previous 
study on AATD analysis showed that polymerase chain 
reaction (PCR) products obtained from serum are of the 
same quality as those obtained from whole blood [16].
Our laboratory has recently focused on AATD popula-
tion screening and rapid diagnosis, including some rare 
variants. We have developed allele-specific genotyping 
and exonic sequencing of SERPINA1 protocols using DNA 
from buccal swabs and residual genomic DNA present in 
serum samples. The aim of this study was to validate the 
use of this kind of samples for the complete laboratory 
study of AATD.
Materials and methods
AAT buccal swab samples
Catch-All Sample Collection Swabs (Epicentre, Madison, WI, USA) 
were used. Patients were asked to gently brush the inside surface 
of both cheeks with the brush, approximately 15 times on each side. 
Samples were then packed and taken to the laboratory where the 
samples were stored at room temperature. Buccal swab samples were 
obtained from 16 individuals previously characterized by IEF and 
exonic sequencing of SERPINA1: 2 MM, 2 MS, 2 MZ, 3 SZ, 3 ZZ, 1 IS, 
1 Z/Plowell, 1 M/Mmalton and 1 S/Mmalton. Both PI I (p.Arg39Cys) 
and PI Plowell (p.Asp256Val) alleles are rare variants. The genotypes 
were unknown to the technician who was blinded.
The study was approved by the Research and Ethics Commit-
tee of the Vall d’Hebron Hospital (Barcelona, Spain) and written 
informed consent was obtained from all the patients for the genetic 
analyses.
DNA extraction from buccal swab samples
DNA was obtained from buccal swab samples using the Quick Extract 
DNA Extraction Solution 1.0 (Epicentre, Madison, WI, USA). Each 
brush was placed into a 1.5 mL plastic tube containing 250 μL of the 
DNA extraction solution and rotated five times. Then, it was pressed 
against the side of the tube and removed from the tube to ensure 
that most of the liquid remained in the tube. The sample was mixed 
by vortex for 10 s and incubated at 65 °C for 1 min. The sample was 
resuspended by vortex mixing and incubated at 98 °C for 2 min. DNA 
samples were stored at − 20 °C.
Allele-specific genotyping assay from buccal swab 
 samples
Genotyping was performed using a LightCycler 480 analyzer 
(Roche Diagnostic, Mannheim, Germany) which achieves rapid 
real-time PCR. We used a commercially available kit with specific 
primers and probes designed for PI S and PI Z mutation detection 
(Tib Molbiol, Berlin, Germany). The protocol for PI Mmalton allele-
specific genotyping has been previously described in detail [17]. All 
samples (DNA extraction from buccal swab samples) were undi-
luted and diluted 1 : 2 and 1 : 10, and a commercial positive control 
was used.
Exonic sequencing of the SERPINA1 gene from buccal 
swab samples
This method consists of the amplification of DNA extracted by PCR 
followed by Sanger automated sequencing of the PCR products. The 
four exons that code the AAT protein were amplified by PCR using 
DNA from buccal swab samples. We used the same primers for both 
PCR and the sequencing methods, and these are shown in Table  1 
(GeneBank accession no. K02212). PCR amplification of each encod-
ing exon was carried out utilizing 2.5 μL of Buffer 10 × with 18 mM 
MgCl2, 0.2  mM of dNTPs (each), 400  mM of forward and reverse 
primers, 0.25 μL of Fast Start High Fidelity Enzyme Blend (Roche 
Table 1: Primer sequences for PCR and genome sequencing of 
SERPINA1.
Exon   Sequence Annealing 
temperature, °C
II A Fw: 5ʹ-GATCACTGGGAGTCATCATGTGC-3ʹ   54
A Rv: 5ʹ-GGTTGAGGGTACGGAGGAGT-3ʹ
B Fw: 5ʹ-CCAAGGCTGACACTCACGAT-3ʹ
B Rv: 5ʹ-AGGAGAGTTCAAGAACTGATGGTT-3ʹ  
III Fw: 5ʹ-TTCCAAACCTTCACTCACCCCTGGT-3ʹ   60
Rv: 5ʹ-CGAGACCTTTACCTCCTCACCCTGG-3ʹ  
IV Fw: 5ʹ-CCCAGAAGAACAAGAGGAATGCTGT-3ʹ   54
Rv: 5ʹ-CATTCTTCCCTACAGATACCATGGT-3ʹ  
V Fw: 5ʹ-TGTCCACGTGAGCCTTGCTCGAGGC-3ʹ   54
Rv: 5ʹ-GACCAGCTCAACCCTTCTTTAATGT-3ʹ  
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Diagnostic, Mannheim, Germany), 1 μL of genomic DNA and PCR 
grade water for a total volume of 25 μL. The PCR program is shown 
in Table  2. The PCR product was purified with 2 μL of ExoSAP-IT 
(Affimetrix, Santa Clara, CA, USA) and subjected to 15 min at 37 °C 
and 15 min at 80 °C. PCR products were directly sequenced using the 
Big Dye X-Terminator 3.1 Cycle Sequencing Kit (Applied Biosystems, 
 Austin, TX, USA).
AAT serum samples
For the design of the techniques, serum samples were obtained from 
two individuals previously characterized by IEF and exonic sequenc-
ing of SERPINA1 as MM and MS. The gold standard for diagnosing 
AATD in our laboratory is the algorithm described in detail previ-
ously [13]. We use the combination of AAT levels, IEF and genotyp-
ing (when required) to obtain the definitive diagnosis. Therefore, 
allele-specific genotyping and exonic sequencing of SERPINA1 proto-
cols using DNA from serum sample were included in this diagnostic 
algorithm. Nineteen individuals were processed due to discrepan-
cies between AAT nephelometric levels and IEF phenotyping and 
their serum samples were incorporated in our diagnostic algorithm. 
Patients with a phenotype showing one or two M alleles, deficient 
AAT serum levels, and without other deficient alleles observed by 
phenotyping were analyzed by the Mmalton genotyping assay. In 
addition, S and Z genotypes were determined in order to test possible 
S and Z variants not correctly characterized by phenotyping. When 
these variants were not detected, exonic sequencing of the SERPINA1 
gene was performed.
DNA extraction from serum samples
DNA was extracted from 200 μL of serum samples using the QIAamp 
DNA Mini Kit (Qiagen, Hilden, Germany) based on the spin column 
technique. The manufacturer’s protocol was followed with one modi-
fication: the final elution was made using 50 μL of water. DNA extrac-
tions were stored at − 20 °C.
Allele-specific genotyping assay from serum samples
Genotyping was performed using the same instrument and protocols 
for PI S, PI Z and PI Mmalton detection described for buccal swab 
samples. In this case, the samples were not diluted.
Exonic sequencing of the SERPINA1 gene from serum 
samples
Serum samples generally yield far lower amounts of DNA than 
whole blood samples, making PCR amplification and sequencing 
difficult. Therefore, two rounds of PCR were necessary to amplify 
the SERPINA1 encoding exons. PCR amplification and sequencing 
were performed using the same primers used in buccal swab sample 
amplification (Table 1). The reaction was conducted at a final vol-
ume of 12.5 μL containing 1.25 μL of Buffer 10 × with 18 mM MgCl2, 
0.2 mM of dNTPs (each), 400 mM of each primer, 0.25 μL of Fast Start 
High Fidelity Enzyme Blend and 7.5 μL of genomic DNA. The ther-
mocycling conditions are described above (Table 2). The second PCR 
round was performed using PCR product from the first round: 2 μL 
of Buffer 10 × with 18 mM MgCl2, 0.2 mM of dNTPs (each), 400 mM 
of forward and reverse primers, 0.2 μL of Fast Start High Fidelity 
Enzyme Blend, 1 μL of genomic DNA and PCR grade water for a total 
volume of 20 μL. Table 3 shows the PCR conditions. The use of two 
rounds of PCR raises the risk of contamination. We therefore followed 
security measures to avoid this event, including the use of four dif-
ferent rooms for DNA extraction, mix preparation, sample addition 
and post amplification steps. In addition, a blank was used in each 
amplification to check for the absence of contamination.
Final PCR product purification and direct sequencing are 
described above.
Results
Buccal swab samples
A total of 16 buccal swab samples from previously char-
acterized individuals were analyzed using the allele- 
specific genotyping assay and sequencing method. All 
the samples assessed gave concordant results with the 
previous characterization. Melting peaks in PI S, PI Z and 
PI Mmalton specific genotyping were clear in all the undi-
luted and diluted DNA samples (1 : 2 and 1 : 10). We chose 
the dilution of 1 : 10 because of its similarity to the positive 
control used. The PI S and PI Z genotyping results from 
a SZ sample are shown in Figure 1. Buccal swab samples 
recovered a large amount of DNA, resulting in easy PCR 
Table 2: PCR program for SERPINA1 amplification.
Step Temperature, °C Time, hh:mm:ss Cycles
Denaturation 95 00:02:00 1
Amplification 95 00:00:30 35
Primer annealing 00:00:30
72 00:00:30
Final extension 72 00:05:00 1
Cooling 4 ∞ 1
Table 3: PCR program for second PCR round for SERPINA1 amplifica-
tion using serum samples.
Step Temperature, °C Time, hh:mm:ss Cycles
Denaturation 95 00:02:00 1
Amplification 95 00:00:30 20
Primer annealing 00:00:30
72 00:00:40
Final extension 72 00:05:00 1
Cooling 4 ∞ 1
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amplification and sequencing, and providing clear, easy 
to interpret results (Figure 2).
Serum samples
For the design of the techniques two samples character-
ized as MM and MS were used. Once the techniques were 
set up, the results obtained by allele-specific genotyping 
and sequencing assays using DNA from serum samples 
were totally concordant with the previous characteri-
zation of the samples. The AATD diagnostic algorithm 
included PI S, PI Z and PI Mmalton specific genotyping 
and direct sequencing methods using serum samples. A 
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Figure 1: Melting peaks of PI S and PI Z variant detection using DNA from buccal swab samples.
(A) Undiluted sample, (B) 1 : 2 diluted sample, (C) 1 : 10 diluted sample, (D) heterozygote positive control, and (E) blank control.
total of 19 serum samples were processed by these tech-
niques because the AAT levels and phenotype were not 
concordant and whole blood or DBS samples were not 
available. Fourteen of the 19  samples were analyzed by 
an allele-specific genotyping assay, achieving definitive 
results: 4 MZ, 1 MS, 1 SZ, 3 ZZ and 5 M/Mmalton. Three 
samples were sequenced because the results were not 
conclusive after the allele-specific genotyping assay: 2 M/
QOMattawa (p.Leu353Phe) and 1 MM. The remaining two 
samples were directly sequenced to confirm the P allele 
detected by IEF: 1 M/Plowell and 1 S/Plowell. Thus, we 
characterized the 19 samples following the complete AATD 
diagnostic algorithm using only serum samples. One case 
deserves special mention: case no. 4  showed discrepant 
Belmonte et al.: New genetic diagnosis for AATD   5
AAT levels (0.64 g/L) and genotype (MM). This patient was 
studied in depth and no exonic or intronic mutations were 
detected. At present, we have no explanation for these dis-
cordant results, and more analyses are ongoing. Table 4 
shows the definitive AAT levels, and the phenotyping and 
genotyping results. Figure 3 shows a sequence fragment 
from one M/QOMattawa patient.
Discussion
Delay in obtaining results is one of the most important 
problems in AATD diagnosis. Early detection of AATD 
would enable individuals to make changes in their life-
style mainly with respect to smoking [18, 19] or environ-
mental or occupational pollution. The objective of our 
study was to increase the number of individuals diag-
nosed with AATD. Once an index case is identified it 
becomes necessary to screen siblings and other family 
members to detect additional severely deficient subjects 
and initiate preventive or even therapeutic measures. Cur-
rently, the use of DBS samples has significantly facilitated 
the laboratory diagnosis of AATD in specialized centers 
[20, 21]. The use of DBS allows easier sample preservation 
and shipping [22, 23]. However, screening may be diffi-
cult in families with widely scattered members, disabled 
individuals or in children and adults with needle phobia. 
Figure 2: Sequence fragment from one M/Mmalton (Phe52del) patient obtained by exonic sequencing of the SERPINA1 gene using DNA from 
a buccal swab sample.
Table 4: AAT levels, phenotyping and genotyping of the cases analyzed using serum samples.
Case no.   AAT levels, 
g/L
  Phenotype   PI S and PI Z genotyping Mmalton genotyping SERPINA1 
sequencing
Definitive 
results
1 0.87  MM – – Mmalton/Non Mmalton – M/Mmalton
2 0.83  MZ Non S/Non S   Z/Non Z – – MZ
3 0.72  MZ Non S/Non S   Z/Non Z – – MZ
4a 0.64  MM – – Non Mmalton/Non Mmalton  MM MM
5 0.6  MM – – Mmalton/Non Mmalton – M/Mmalton
6 0.81  MP – – – M/Plowell M/Plowell
7 0.84  MZ Non S/Non S   Z/Non Z – – MZ
8 0.88  MS S/Non S Non Z/Non Z   – – MS
9 0.71  MM – – Mmalton/Non Mmalton – M/Mmalton
10 0.49  ZZ Non S/Non S   Z/Z – – ZZ
11 0.68  MM – – Non Mmalton/Non Mmalton  M/QOMattawa M/QOMattawa
12 0.94  MM – – Non Mmalton/Non Mmalton  M/QOMattawa M/QOMattawa
13 0.85  PS – – – Plowell/S Plowell/S
14 0.81  MM – – Mmalton/Non Mmalton   – M/Mmalton
15 0.36  ZZ Non S/Non S Z/Z – – ZZ
16b 0.53  MZ Non S/Non S Z/Z – – ZZ
17 0.92  SZ S/Non S Z/Non Z – – SZ
18 0.74  MZ Non S/Non S Z/Non Z – – MZ
19 0.72  MM – – Mmalton/Non Mmalton – M/Mmalton
aThis patient was studied in depth and no exonic or intronic mutations were detected. bThis patient was receiving AAT augmentation 
therapy. Therefore, phenotype reveals both the patient’s own AAT phenotype, as well as the normal phenotype of the protein included in the 
treatment. –, Following our diagnostic algorithm of AATD, a definitive result had already been obtained, and therefore this technique was 
unnecessary.
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The current study describes a fast, simple means for col-
lecting, delivering and preparing genomic DNA using 
buccal swab brushes. This kind of sample can be collected 
by individuals without training, minimizes exposure to 
blood borne pathogens and avoids patient distress, poten-
tially facilitating the participation of family members in 
genetic studies [24]. In addition, samples are stable for 
up 1 month at room temperature, are inexpensive to ship 
and require no special storage conditions. DNA extraction 
requires only heat treatment and centrifugation without 
the use of toxic organic solvents, allowing a large number 
of samples to be processed in < 1 h. In this study, buccal 
swab samples were assessed as an alternative to DBS 
samples for AATD family studies. In this sense, Carroll 
et al. [25] reported the use of buccal swab DNA samples in 
a study of the prevalence of AATD in Ireland. In this case, 
samples were screened to detect PI S and PI Z variants by 
real-time PCR. In our study, we performed PI S, PI Z and PI 
Mmalton detection using real-time PCR as well as exonic 
sequencing of SERPINA1, which has not been described 
previously.
The AATD diagnostic algorithm consists of four funda-
mental steps: AAT serum levels determination, IEF pheno-
typing, allele-specific genotyping and direct sequencing. 
The latter technique requires EDTA whole blood or DBS 
samples, which are usually not available in the laboratory, 
and most of these patients do not return to the examina-
tion room for sample extraction. In this sense, it should 
be kept in mind that routine AATD studies (AAT levels 
and IEF phenotyping) are performed in serum samples. 
In this study a total of 19 serum samples were genotyped 
by the allele-specific genotyping assay or direct sequenc-
ing. Although serum samples generally result in the recov-
ery of a much smaller amount of DNA than whole blood 
samples, the quantity of DNA obtained by two rounds of 
amplification was adequate for sequencing and achieving 
clear results. In our case, we performed exonic sequencing 
because most of the mutations described of the SERPINA1 
gene are located in exons [26]. However, there are some 
null variants such as QOMadrid (c.-5+2dupT), QOporto 
Figure 3: Sequence fragment from one M/QOMattawa (Leu353Phe) patient obtained by exonic sequencing of the SERPINA1 gene using DNA 
from a serum sample.
(c.-5 + 1G > A), QOwest (c.-4 + 1G > T) and QOBonny Blue 
(c.-4 + 1Gdel) that cause mutations located in the regula-
tory regions of the gene (introns) that affect the mecha-
nisms of transcription and alternative splicing of the 
SERPINA1 gene [27, 28]. Intronic sequencing is necessary 
in these cases, and serum samples could also be an ade-
quate source of DNA to perform this technique. Therefore, 
the implementation of this protocol in the diagnostic algo-
rithm may contribute to the detection of PI S and PI Z vari-
ants as well as rare alleles while also performing routine 
studies.
This represents an important improvement of the 
algorithm for “in vitro” AATD studies at a clinical level. 
Similarly, Bornhorst et al. [29] reported the first protocol of 
AAT sequencing from serum samples that incorporates a 
commercial DNA extraction method. Our proposed meth-
odology is similar but uses different primers and ampli-
fication protocols. Moreover, we have incorporated this 
method in our AATD diagnostic algorithm and have used 
it with routine samples. Our method yields adequate DNA 
for allele-specific genotyping and direct sequencing of all 
serum samples.
Despite the accuracy of the results, one possible short-
coming of this study is the small sample size. Therefore, 
future studies involving a larger number of samples are 
necessary to reassert the utility of these kinds of samples 
in the diagnosis of AATD. Nonetheless, this can be con-
sidered a preliminary validation study showing proof of 
principle but requiring further validation.
Conclusions
Widespread use of the methodologies described above 
could optimize the accuracy of AATD diagnosis and 
promote the expansion of screening programs. We have 
developed two methods for the early diagnosis of AATD 
which are simple and easy to perform by physicians and 
lab technicians and provide early results for patients.
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